2010
Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer
Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L. Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. Clinical Cancer Research 2010, 16: 5351-5361. PMID: 20829329, PMCID: PMC4181852, DOI: 10.1158/1078-0432.ccr-10-1265.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, PharmacologicalBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCyclophosphamideDoxorubicinFemaleFluorouracilGene Expression Regulation, NeoplasticHumansMiddle AgedPaclitaxelPredictive Value of TestsPrognosisTreatment OutcomeConceptsPositive predictive valuePathologic complete responseFAC armPCR rateBreast cancerPredictive valueGene expression profilingDifferent molecular subsetsFine-needle aspiration biopsyMulticenter Randomized TrialInternational clinical trialsGenomic predictorsNegative predictive valueTreatment response predictionWeekly paclitaxelNeoadjuvant chemotherapyCyclophosphamide chemotherapyFAC chemotherapyPreoperative chemotherapyComplete responseRandomized trialsTreatment armsPredictive markerClinical trialsMolecular subsets
2009
Evaluation of the Predictive Performance and Regimen Specificity of a 30-Gene Predictor of Pathologic Complete Response in a Prospective Randomized Neoadjuvant Clinical Trial for Stage I-III Breast Cancer.
Tabchy A, Symmans W, Valero V, Vidaurre T, Lluch A, Qi Y, Souchon E, Barajas-Figueroa L, Gomez H, Martin M, Coutant C, Hess K, Hortobagyi G, Pusztai L. Evaluation of the Predictive Performance and Regimen Specificity of a 30-Gene Predictor of Pathologic Complete Response in a Prospective Randomized Neoadjuvant Clinical Trial for Stage I-III Breast Cancer. Cancer Research 2009, 69: 101-101. DOI: 10.1158/0008-5472.sabcs-09-101.Peer-Reviewed Original ResearchPathologic complete responsePositive predictive valueCourses of FACFAC armWeekly paclitaxelFAC chemotherapyPCR rateComplete responseMultigene predictorsTreatment armsBreast cancerStage IPathologic complete response rateGenomic predictorsComplete response rateNeoadjuvant clinical trialsEstrogen receptor statusNegative predictive value 88Treatment response predictionFAC regimenNPV 92Neoadjuvant chemotherapyOnly chemotherapyCyclophosphamide chemotherapyNodal status
2007
The impact of hormone receptor status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab
Peintinger F, Buzdar A, Kuerer H, Gonzalez-Angulo A, Hatzis C, Pusztai L, Esteva F, Green M, Hortobagyi G, Symmans W. The impact of hormone receptor status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab. Journal Of Clinical Oncology 2007, 25: 533-533. DOI: 10.1200/jco.2007.25.18_suppl.533.Peer-Reviewed Original ResearchHER2-positive breast cancerResidual cancer burdenHR-negative patientsAddition of trastuzumabHormone receptor statusPathologic complete responseNeoadjuvant chemotherapyBreast cancerPathologic responseReceptor statusResidual diseaseHER2-positive diseaseHR-positive patientsPathologic response rateSimilar pCR ratesHER2-positive patientsStandard neoadjuvant chemotherapyConcurrent trastuzumabRCB-IIRCB-IIIFAC chemotherapyPathologic reviewPCR rateComplete responseLymph nodesHER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer
Pusztai L, Andre F, Mazouni C, Liedtke C, Kau S, Frye D, Green M, Gonzalez-Angulo A, Symmans W, Hortobagyi G. HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer. Journal Of Clinical Oncology 2007, 25: 548-548. DOI: 10.1200/jco.2007.25.18_suppl.548.Peer-Reviewed Original ResearchPathologic complete responseHER2 overexpressionPCR rateBreast cancerER- cancersHER2- diseaseHER2 expressionRelapse-free survival rateER-negative statusWeekly paclitaxel regimenMicrotubule associated protein tauHigh nuclear gradePaclitaxel regimenPreoperative paclitaxelFAC chemotherapyPreoperative chemotherapyComplete responseHER2 tumorsHER2 statusDoxorubicin chemotherapyNuclear gradeRetrospective analysisPatientsTaxane sensitivitySurvival rateHER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Research And Treatment 2007, 108: 183-190. PMID: 17468948, DOI: 10.1007/s10549-007-9594-8.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclophosphamideDisease-Free SurvivalDNA Topoisomerases, Type IIDNA-Binding ProteinsDoxorubicinDrug Administration ScheduleFemaleFluorouracilGene AmplificationGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedNeoadjuvant TherapyNeoplasm StagingOligonucleotide Array Sequence AnalysisPaclitaxelPatient SelectionPoly-ADP-Ribose Binding ProteinsReceptor, ErbB-2Receptors, EstrogenRetrospective StudiesRNA, MessengerTau ProteinsTime FactorsTreatment OutcomeConceptsPathologic complete responseHER2 overexpressionBreast cancerFAC chemotherapyPCR rateER statusHER2 expressionRelapse-free survival rateHER2-overexpressing breast cancerMicrotubule associated protein tauER-positive cancersEstrogen receptor statusPreoperative chemotherapyComplete responseHER2 tumorsMethodsRetrospective analysisReceptor statusPatientsSurvival rateMultivariate analysisWeekly scheduleMAP-tauProtein tauCancerChemotherapy
2004
Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips
Pusztai L, Wang J, Coombes K, Hoersch S, Ayers M, Ross J, Hess K, Hortobagyi G, Symmans W, Stec J. Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips. Journal Of Clinical Oncology 2004, 22: 503-503. DOI: 10.1200/jco.2004.22.14_suppl.503.Peer-Reviewed Original ResearchCross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips
Pusztai L, Wang J, Coombes K, Hoersch S, Ayers M, Ross J, Hess K, Hortobagyi G, Symmans W, Stec J. Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips. Journal Of Clinical Oncology 2004, 22: 503-503. DOI: 10.1200/jco.2004.22.90140.503.Peer-Reviewed Original ResearchPharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma
Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright GL, Drake RR, Vlahou A. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 2004, 100: 1814-1822. PMID: 15112261, DOI: 10.1002/cncr.20203.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBiopsy, NeedleBreast NeoplasmsCase-Control StudiesChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Administration ScheduleFemaleFluorouracilHumansMastectomyMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelPostoperative CarePreoperative CareProteomicsRisk AssessmentSensitivity and SpecificitySurvival AnalysisTreatment OutcomeConceptsBreast carcinomaHealthy womenPreoperative chemotherapyFinal tumor responseSubset of patientsDay 3 posttreatmentAdjuvant chemotherapyPostoperative chemotherapyCyclophosphamide chemotherapyFAC chemotherapyMicrometastatic diseasePaclitaxel chemotherapyNormal womenTumor responsePlasma profilesHealthy volunteersChemotherapyPatientsStage ICarcinomaDay 0Single courseWomenPlasma samplesCandidate markersChanges in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy
Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004, 25: 94-102. PMID: 14698135, DOI: 10.1016/j.cyto.2003.10.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsAnxietyBloodBreast NeoplasmsCyclophosphamideCytokinesData Interpretation, StatisticalDoxorubicinFatigueFemaleFluorouracilHumansInterleukin-1Interleukin-10Interleukin-12Interleukin-6Interleukin-8Middle AgedNauseaPaclitaxelPainPatient SelectionQuality of LifeTumor Necrosis Factor-alphaConceptsFlu-like symptomsIL-10 levelsIL-6IL-8IL-10Paclitaxel groupHealthy volunteersPaclitaxel chemotherapyJoint painIL-12Inflammatory cytokinesPlasma levelsTNF-alphaDay 3Single-agent paclitaxelBaseline cytokine levelsIL-8 levelsTransient side effectsHigh-dose treatmentWeekly paclitaxelCytokine levelsFAC chemotherapyMusculoskeletal symptomsCancer patientsIL-1beta